articles BACKGROUND Increased growth and contraction of vascular smooth muscle cells (VsMCs) are major abnormalities in many vascular disorders. to investigate the signaling pathways that mediate these processes, we studied the expression of smooth muscle myosin light chain kinase (smMLCK) in VsMCs.
Vascular reactivity and remodeling represent crucial events in the development of many diseases such as atherosclerosis, intimal hyperplasia, and hypertension. Angiotensin II (Ang II) plays a primary role in many vascular disorders by stimulating vascular smooth muscle cell (VSMC) contraction, proliferation, and migration. Ang II is a powerful contractile agonist that plays a central role in hypertension, and drugs that inhibit Ang II signaling are used extensively to treat high blood pressure in humans. 1 Ang II is also a potent mitogen that causes structural alterations in the vessel wall by stimulating the hypertrophy and hyperplasia of VSMCs in hypertension. 2 Importantly, angiotensin-converting enzyme inhibitors and Ang II-receptor antagonists inhibit development of VSMC medial hypertrophy in a variety of hypertensive animal models. 3, 4 Although it is clear that Ang II triggers a complex cascade of signaling events in many vascular diseases, how these signaling events are integrated to regulate contractility and remodeling is poorly understood.
One pathway that could play an important part of Ang II signaling is Ras. Ras is activated by mitogenic stimuli, including Ang II, 2 and Ras mutations are common in transformed cells. 5 Ras, via MAP kinase kinase (MEK) and the phosphorylation and activation of extracellular signal-regulated kinase (ERK), stimulates gene expression and drives progression through the cell cycle. 6 Ras has been implicated in a variety of cardiovascular diseases 7 and Ras appears to play a direct role in regulating VSMC proliferation because the hyperplasia suppressor gene, an important regulator of VSMC proliferation, induces cell-cycle arrest by inhibiting Ras/MEK/ERK signaling. 8 Other experiments have shown that Ang II induces ERK activation and regulates the expression of genes involved in the proliferation of VSMCs. 2 What, then, lies downstream of Ang II and Ras? One possibility is smooth muscle myosin light chain kinase (smMLCK) and myosin light chain phosphorylation (MLC-P). ATP hydrolysis by actin and myosin II plays a crucial role in VSMC contractility, motility, and proliferation. Cross-bridge cycling by actin-myosin II is regulated by the phosphorylation and dephosphorylation of the 20-kDa regulatory light chain of myosin II (MLC 20 ). 9, 10 Phosphorylation of MLC 20 (MLC-P) is regulated by the calcium/calmodulin-dependent enzyme myosin light chain kinase (smMLCK). MLC 20 dephosphorylation is catalyzed by myosin phosphatase 1(MPase1) 11 and the balance between MLCK and MPase1 activity determines the intracellular level of MLC-P and force generated by smooth muscle. 9 Rho is also important in regulating VSMC contractility. [12] [13] [14] Rho kinase inhibits MPase1 activity by phosphorylating the myosin-binding subunit of MPase1. 12 articles
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Rho A levels are increased in spontaneously hypertensive rats (SHRs) 13 and a Rho kinase inhibitor decreases blood pressure in a number of models of hypertension. 14 These data suggest an important role for Rho in hypertension via a mechanism that increases MLC-P by inhibiting MPase1.
Although Ang II is known to activate smMLCK by increasing intracellular calcium, 15 relatively few studies have focused on how Ang II signaling controls smMLCK gene expression. Therefore, we investigated the molecular mechanisms that regulate the expression of smMLCK by Ang II in primary VSMCs isolated from normotensive Wistar-Kyoto (WKY) rats. We also studied SHRs because it is a well-established model of essential hypertension 16 in which the increase in blood pressure involves increases in VSMC proliferation 17 and contractility. 18 Moreover, arteries from SHRs have increased medial mass compared to the arteries from normotensive rats. 17 Thus, VSMCs from SHRs and WKY rats provide a unique experimental system for investigating Ang II-Ras signaling. Our data show that Ang II rapidly increases Erk activation, followed by increases in smMLCK expression and MLC-P. Furthermore, inhibiting Ang II type 1 (AT1) receptor, Ras, or MEK blocked the Ang II-induced increases in smMLCK expression. We also report that blocking MEK or MLCK in vivo decreases blood pressure and medial thickening in mesenteric arteries.
METHODS
Cell culture and immunoblot analyses. VSMCs explanted 19 from aortas of 4-7-week-old WKY rats were serum starved overnight and treated with 0.1 μmol/l Ang II (Calbiochem, La Jolla, CA) and/or 10 μmol/l U0126 (A.G. Scientific, San Diego, CA). Cells were transfected with 0.5 µg of N17Ras or empty vector (pcDNA 3.1) using lipofectamine (Invitrogen, Carlsbad, CA). For immunoblot analyses, cells were treated with 10% trichloroacetic acid and 10 mmol/l dithiothreitol and washed with ether three times. After briefly air-drying the samples to remove the ether, cellular proteins were extracted in buffer containing 9 mol/l urea, 10 mmol/l dithiothreitol and 20 mmol/l Tris, pH 8.0. After measuring the protein concentrations using a BioRad Protein Assay (BioRad, Richmond, CA), equivalent amounts of proteins (30 µg) were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis or urea-glycerol polyacrylamide gel electrophoresis. 20 Sodium dodecyl sulfate gels were transferred to nitrocellulose and probed with an antibody to smMLCK, 21 Rho A or phosphorylated MPase1 (Santa Cruz Biotechnology, Santa Cruz, CA), total or phosphorylated ERK1/2 (Cell Signaling Technology, Beverly, MA), or the broad specificity C4 antibody to actin. 22 Urea-glycerol polyacrylamide gel electrophoresis was used to separate the unphosphorylated and phosphorylated forms of MLC 20 and the stoichiometry of phosphorylation (mol PO 4 /mol MLC 20 ) was calculated as described previously. 23, 24 Immunoreactive bands were visualized using enhanced chemiluminescence (Amersham Pharmacia Biotech, Piscataway, NJ) and quantified densitometrically.
Animals and procedures.
All animal procedures were performed with prior approval of the University of Illinois at Chicago Animal Care Committee and in accordance with National Institutes of Health guidelines. Male SHRs and WKY rats (Harlan, Indianapolis, IN) received standard chow (Harlan) and water ad libitum. Systolic blood pressure (SBP) was measured twice a week using tail-cuff sphygmomanometry (IITC Incorporated/Life Sciences Institute, Woodland Hills, CA). Each time, a minimum of five SBP readings was taken from each animal. For drug delivery, 16-week-old rats were anesthetized with ether and an osmotic pump (DURECT, Cupertino, CA) was implanted subcutaneously in the shoulder using aseptic technique. The pumps (2-ml capacity, delivery rate of 2.45 µl/h) were filled with 13.5 mmol/l U0126 or 27 mmol/l ML-7 (BIOMOL, Plymouth Meeting, PA) dissolved in 50% dimethyl sulfoxide or vehicle alone. These concentrations were empirically determined to decrease blood pressure without having obvious side effects. 24 Three weeks later, rats were killed and the arteries were excised. Mesenteric arteries were processed for histology, while aortas were immediately placed in ice-cold acetone containing 10% trichloroacetic acid and 10 mmol/l dithiothreitol. Endothelial cells were removed by gently rubbing the inside of the aortas with a cell lifter and connective tissue was removed by dissection. Cleaned aortas were frozen on dry ice and stored at −80 °C for immunoblot analysis.
Histological analysis. The superior mesenteric artery immediately distal to the aorta was fixed in formalin and embedded in paraffin blocks. Cross-sections (5-µm thick) were cut, deparaffinized, and stained with Gomori's Trichrome. Nuclei were visualized with Weigert's iron hematoxylin. Stained sections were examined using a Nikon Eclipse E400 microscope. Total medial cross-sectional area was quantified using ImageJ 1.32 software (National Institutes of Health, Bethesda, MD).
Statistical analysis.
Results are expressed as mean ± s.d. Data were analyzed using an unmatched Student's t-test. Differences at P < 0.05 were considered statistically significant.
RESULTS

Ang II increases smMLCK expression and MLC-P
We began by studying the effects of Ang II on regulating smMLCK and GTPases. Primary cultures of VSMCs from the aortas of WKY rats were treated with 0.1 μmol/l Ang II for the indicated times and subjected to western blot analyses (Figure 1a) . ERK was phosphorylated within 5 min of Ang II treatment while total ERK expression remained unchanged. After ERK activation, smMLCK protein expression was induced rapidly, increasing by 2.56 ± 0.8-fold at 30 min and by 3.0 ± 1.37-fold at 60 min compared with control (Figure 1a,b) . MLC-P also increased from 0.17 ± 0.11 mol PO 4 /mol MLC in control cells to 0.7 ± 0.17 and 0.83 ± 0.15 mol PO 4 /mol MLC at 30 and 60 min after Ang II treatment (Figure 1a,c) . In contrast, there were no significant changes in the expression of Rho A (Figure 1a) or MPase1 (not shown) or the phosphorylation of articles
Regulation of MLCK Expression by Ang II in Hypertension
MPase1 at Thr 696 (P-MPase1), the site phosphorylated by Rho kinase 11 (Figure 1a) , after Ang II treatment. These data indicate that Ang II increases smMLCK expression and MLC-P by activating ERK without substantially affecting Rho-regulated activity of MPase1.
Blocking the AT1 receptor, Ras, or MEK decreases smMLCK expression in vitro
We next investigated which Ang II receptor mediates the smMLCK expression. AT1 and AT2 receptors have been well characterized and known to mediate different cellular processes. Because the AT1 receptor is associated with vasoconstriction and sodium re-absorption, and the AT2 receptor is thought to mediate bradykinin-induced vasodilation and NO release, 1 the increase in smMLCK expression was most likely to be mediated by the AT1 receptor. To test this idea, we treated the VSMCs with losartan, an AT1 blocker, before treating cells with Ang II. Figure 2 shows that Ang II increases MLCK expression and the phosphorylation of ERK (ERK-P; lane 3) and that losartan blocks the Ang II-stimulated increase in smMLCK expression and ERK-P (lane 4). In contrast, 1 μmol/l of PD123319, an AT2 blocker, did not inhibit the smMLCK expression (not shown).
The role of ERK in mediating Ang II-regulated smMLCK expression and MLC-P was investigated further by either transfecting VSMCs with a vector containing dominantnegative Ras (N17Ras) or treating the cells with U0126. Expression of N17Ras in VSMCs decreased MLC-P in control cells (Figure 3a, lane 3) and Ang II-stimulated increases in smMLCK expression, MLC-P, and ERK-P (Figure 3a, lane 4) . articles
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U0126, a specific inhibitor of MEK, 25 which is an upstream regulator of ERK in Ras signaling, 7 also blocked the Ang II-induced smMLCK expression, MLC-P, and ERK-P to the levels seen in untreated control cells (Figure 3b, lane 4) . These data add substantial support to the idea that Ang II regulates smMLCK expression and MLC-P primarily via the AT1 receptor and the activation of the Ras-MEK-ERK cascade.
Inhibiting MEK decreases vascular remodeling and blood pressure in SHRs
Because SHRs have increased medial thickness and decreased luminal diameter, 26 we investigated the importance of MEK/ ERK activities in vascular remodeling in SHRs. For this, we delivered U0126 to adult SHRs that were 16 weeks old at the start of the experiment. We used osmotic pumps containing 13.5 mmol/l U0126 to deliver the drug constantly for 3 weeks as previously described. 24 The systolic blood pressure was 144 ± 6.7 mm Hg in normotensive WKY rats and 221.6 ± 10.2 mm Hg in the control SHRs receiving dimethyl sulfoxide for 3 weeks (Figure 4a) . In contrast, it decreased to 181.4 ± 2.18 mm Hg in SHRs receiving U0126 for 3 weeks. Moreover, consistent with our previous study, 24 the levels of smMLCK expression, MLC-P and ERK-P were decreased in aortas removed from U0126-treated SHRs compared with control (Figure 4b ), although these levels remain somewhat elevated compared with those in WKY rats. Furthermore, U0126 resulted in decreases in the medial mass in mesenteric arteries of SHRs receiving U0126 compared with controls (Figure 4c) . The total medial area measured using NIH ImageJ software was 2.35 ± 0.06 (relative units) in SHRs receiving vehicle and 1.33 ± 0.07 in SHRs receiving U0126 (Figure 4d ). These data demonstrate that inhibiting MEK decreases vascular thickening in SHRs.
Inhibiting smMLCK decreases vascular thickening and blood pressure in SHRs
We next investigated the importance of smMLCK activity in regulating vascular remodeling in vivo by treating SHRs with ML-7, a specific inhibitor of smMLCK. ML-7 was delivered to 16-week-old SHRs for 3 weeks using osmotic pumps. Again, dimethyl sulfoxide had no effect on blood pressure and the SBP was 221.6 ± 18.6 mm Hg in control SHRs receiving dimethyl sulfoxide for 3 weeks. In contrast, ML-7 lowered SBP to 165.0 ± 7.8 mm Hg in SHRs (Figure 5a) . Histological analysis revealed a thinner medial smooth muscle layer in mesenteric arteries from SHRs receiving ML-7 compared with controls (Figure 5b) . The total medial area of mesenteric arteries measured using NIH ImageJ software was 2.51 ± 0.17 (relative units) for SHRs receiving vehicle and 1.47 ± 0.13 for SHRs receiving ML-7 (Figure 5c ). These data demonstrate that inhibiting MLCK decreases vascular thickening in mesenteric arteries of SHRs. articles
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DISCUSSION
The data presented in this paper demonstrate an important role for smMLCK expression and MLC-P in the vascular effects of Ang II. Ang II stimulation results in rapid smooth muscle contractions. It is also a trophic factor that stimulates transcription and translation in VSMCs. However, the signaling mechanisms that integrate the effects of Ang II on vascular remodeling and reactivity are largely unknown. MLC-P is in a unique position to integrate both effects of Ang II. A central role for MLC-P in regulating contraction is well established 10 and its importance in cell division is also becoming clear. MLC-P by MLCK is critical for the progress of cytokinesis in Drosophila and mammalian cells 20, [27] [28] [29] and MLCK is localized in the cleavage furrow of dividing mammalian cells. 20 MLC-P and smMLCK are also important in determining cell fate. MLC 20 are dephosphorylated during apoptosis and inhibiting smMLCK is sufficient to induce apoptosis in VSMCs. 30 Moreover, inhibiting MLCK retarded the proliferation of breast and prostate cancer cells, in vivo. 31 Thus, the induction of smMLCK expression by Ang II could contribute to both abnormal VSMC proliferation and contractility in hypertension.
To investigate this possibility, we studied the regulation of smMLCK expression in blood vessels from normotensive and hypertensive rats. 24 These studies revealed that smMLCK expression and MLC-P are increased in SHRs compared with age-matched WKY rats. They showed that the rat smMLCK promoter contains a CArG box, a transcriptional element that binds serum response factor (SRF). In addition, the smMLCK promoter in SHRs contains a 12-bp insertion adjacent to the CArG box not found in normotensive rats. This insertion increases SRF binding to the CArG box and SRF-dependent smMLCK gene expression. The increase in smMLCK expression was blocked by dominant-negative SRF or dominant-negative Ras whereas inhibiting MEK in vivo decreased smMLCK expression and blood pressure in SHRs partly by decreasing SRF binding to the smMLCK promoter. 24 Other studies showed that treating SHRs with captopril, an angiotensin-converting enzyme inhibitor, decreased smMLCK expression in concert with decreases in vascular thickening and blood pressure. 32 On the basis of these data, we hypothesized that Ang II-regulated smMLCK expression plays a critical role in the development of hypertension.
Here we show that Ang II regulates smMLCK expression and MLC-P via the Ras-MEK-ERK cascade (Figure 1) . The data also show that losartan, which is an AT1 receptor antagonist 1 (Figure 2) blocks Ang II-mediated increases in smMLCK expression and MLC-P. Moreover, blocking Ras signaling downstream of the AT1 receptor using pharmacological (U0126, Figures 3b and 4b) or recombinant (dominant-negative Ras, Figure 3a ) approaches also decrease smMLCK expression and MLC-P in VSMCs. We also show that inhibiting either MEK or smMLCK decreases VSMC proliferation and blood pressure in SHRs. Taken together, these data strongly support the importance of smMLCK expression and its regulation by Ang II via Ras in vascular remodeling.
Ang II also has short-and long-term effects on vascular smooth muscle. Acutely, Ang II produces calcium transients that return almost to the baseline level within 1 min after stimulation. 2, 15 This transient is predicted to lead to the rapid activation of smMLCK, an increase in MLC-P and smooth muscle contraction and acute, local changes in vasomotor tone. The long-term effects of Ang II appear to involve the activation of the Ras pathway. 7 Ras activation, in turn, results in expression of target genes that lead to both vascular remodeling and chronic contraction of resistance vessels. Interestingly, N17Ras decreases MLC-P without substantially affecting the expression of smMLCK (Figure 3a, lane 3) . While this could reflect the inhibition of phosphorylation and activation of smMLCK by ERK, 33 additional experiments are required to verify this mechanism. Furthermore, our data clearly demonstrate that N17Ras and U0126 specifically block Ang II-induced increases in smMLCK expression, indicating that the MLCK gene is one of the targets of Ras signaling and that smMLCK expression is increased in SHRs. The presence of more smMLCK in hypertensive blood vessels could also make them hyper-responsive to acute agonist stimulation, thereby exacerbating the contractile response. Consequently, increases in smMLCK expression and MLC-P appear to be important aspects of both the shortand long-term effects of Ang II in hypertension.
Because the general toxicity of ML-7 has not been described, we examined the effects of ML-7 on normotensive rats. The body weight was not significantly different in WKY rats after 3 weeks of treatment with either ML-7 or vehicle (not shown). The blood pressure slightly decreased during the first 10 days of ML-7 treatment but recovered by 14 days and remained normal for the rest of the treatment period (not shown). Daily observation showed that the rats were active, their coats were shiny, and they did not have diarrhea, respiratory problems or infections. These data indicate the absence of any obvious toxic effects in rats receiving ML-7. It is worth noting that the in vivo effects of U0126 on blood pressure was also minor in the normotensive rats. 24 Taken together, ML-7 and U0126 decrease high blood pressure in SHRs without substantially changing blood pressure in normotensive rats or having any obvious toxicity.
In summary, we report that Ang II, a primary antagonist responsible for the development of hypertension, increases smMLCK expression and MLC-P (Figures 1 and 2) via Ras and the activation of MEK and ERK (Figure 3) . Importantly, inhibiting MEK or smMLCK decreases vascular remodeling and blood pressure in SHRs (Figures 4 and 5) . These data establish a central role for smMLCK/MLC-P in the pathophysiology of vascular disorders and suggest that inhibiting smMLCK could be useful in treating vascular disorders such as hypertension.
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